V Serebruany

Summary

Publications

  1. ncbi Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel?
    Alex I Malinin
    Johns Hopkins University, Baltimore, MD, USA
    Am Heart J 145:397-403. 2003
  2. ncbi Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD, USA
    Am J Med 119:113-6. 2006
  3. ncbi Dyspnoea after antiplatelet agents: the AZD6140 controversy
    V L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Towson, MD, USA
    Int J Clin Pract 61:529-33. 2007
  4. doi The in vitro effects of niacin on platelet biomarkers in human volunteers
    Victor Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, Maryland 21204, USA
    Thromb Haemost 104:311-7. 2010
  5. doi The antiarrhythmic properties of quifenadine, H1-histamine receptor blocker in children with premature beats: a randomized controlled pilot trial
    Leonid Makarov
    Center for Syncope and Cardiac Arrhythmia in Children and Adolescents of Federal Medico biological Agency Clinical Hospital Moscow, Russia
    Am J Ther 17:396-401. 2010
  6. doi Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge
    Victor L Serebruany
    Dr Serebruany, HeartDrug Research Laboratories, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, MD 21204, USA, Tel 1 410 847 9490, Fax 1 443 583 0205, E mail
    Thromb Haemost 111:3-7. 2014
  7. ncbi Cangrelor infusion is associated with an increased risk for bleeding: meta-analysis of randomized trials
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, MD 21204, United States Electronic address
    Int J Cardiol 169:225-8. 2013
  8. doi Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive
    Victor L Serebruany
    Johns Hopkins University, Baltimore, MD, USA
    Cardiology 126:35-40. 2013
  9. ncbi Mortality after clopidogrel in the non-invasive PLATO cohort and TRILOGY ACS trial: another mismatched death paradox
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, MD, 21204, United States Electronic address
    Int J Cardiol 168:640-2. 2013
  10. doi Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, Maryland, 21204, USA
    Thromb Haemost 110:5-10. 2013

Detail Information

Publications109 found, 100 shown here

  1. ncbi Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel?
    Alex I Malinin
    Johns Hopkins University, Baltimore, MD, USA
    Am Heart J 145:397-403. 2003
    ..Currently conducted clinical trials (Warfarin and Antiplatelet Therapy in Chronic Heart Failure [WATCH] and Plavix Use for Treatment of Congestive Heart Failure [PLUTO-CHF] should clarify the role of clopidogrel in these patients...
  2. ncbi Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD, USA
    Am J Med 119:113-6. 2006
    ..There is also emerging evidence that these side effects of SSRIs are due to blockade of serotonin reuptake in platelets and subsequent platelet dysfunction...
  3. ncbi Dyspnoea after antiplatelet agents: the AZD6140 controversy
    V L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Towson, MD, USA
    Int J Clin Pract 61:529-33. 2007
    ....
  4. doi The in vitro effects of niacin on platelet biomarkers in human volunteers
    Victor Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, Maryland 21204, USA
    Thromb Haemost 104:311-7. 2010
    ..These preliminary data, while intriguing, require confirmation in subjects receiving orally dosed extended-release niacin in order to determine whether these findings are clinically relevant...
  5. doi The antiarrhythmic properties of quifenadine, H1-histamine receptor blocker in children with premature beats: a randomized controlled pilot trial
    Leonid Makarov
    Center for Syncope and Cardiac Arrhythmia in Children and Adolescents of Federal Medico biological Agency Clinical Hospital Moscow, Russia
    Am J Ther 17:396-401. 2010
    ..Although, H(1)-histamine receptor blocker is less potent than amiodarone, much better safety profile of quifenadine is advantageous, especially in children. Future large trials with proving novel antihistamines pleiotropy are warranted...
  6. doi Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge
    Victor L Serebruany
    Dr Serebruany, HeartDrug Research Laboratories, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, MD 21204, USA, Tel 1 410 847 9490, Fax 1 443 583 0205, E mail
    Thromb Haemost 111:3-7. 2014
    ..The ongoing FDA cangrelor review should focus on appropriate event count and/or possible mismatch between site-reported and extra adjudicated events in the CHAMPION-PHOENIX trial. ..
  7. ncbi Cangrelor infusion is associated with an increased risk for bleeding: meta-analysis of randomized trials
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, MD 21204, United States Electronic address
    Int J Cardiol 169:225-8. 2013
    ..However, lack of uniform reporting and adjudication of bleeding events might prevent objective evaluation of the efficacy/safety profile of antithrombotic agents...
  8. doi Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive
    Victor L Serebruany
    Johns Hopkins University, Baltimore, MD, USA
    Cardiology 126:35-40. 2013
    ..Among 3 DAPT options on top of ASA, clopidogrel seems to represent the safest alternative, although comprehensive data on direct prasugrel-associated GI effects are lacking or inconclusive. ..
  9. ncbi Mortality after clopidogrel in the non-invasive PLATO cohort and TRILOGY ACS trial: another mismatched death paradox
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, MD, 21204, United States Electronic address
    Int J Cardiol 168:640-2. 2013
    ..Recently published data focused on outcomes in patients after non-invasive strategies yielded from the PLATO (PLATO-NIS) and TRILOGY ACS trials allowing comparison of all cause mortality (ACM) between trials...
  10. doi Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, Maryland, 21204, USA
    Thromb Haemost 110:5-10. 2013
    ..Low clinical utilisation of prasugrel and especially ticagrelor worldwide in general, and Europe in particular suggests mismatch of prescription habits with issued ESC recommendations. ..
  11. ncbi Ticagrelor FDA approval issues revisited
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Towson, MD 21204, USA
    Cardiology 122:144-7. 2012
    ..The approval was granted following ticagrelor secondary reviews, and review of complete response by FDA officials...
  12. ncbi Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Towson, Maryland 21204, USA
    Thromb Haemost 108:412-4. 2012
    ..The regulatory authorities should consider independent audits when there is a major disagreement between centrally adjudicated and site reported events influencing the results of a major clinical trial...
  13. doi Extreme all-cause mortality in JUPITER requires reexamination of vital records
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Towson, MD 21204, USA
    Cardiology 120:84-8. 2011
    ..To compare all-cause mortality in JUPITER with other statin trials at 21 months of follow-up...
  14. ncbi Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Towson, MD 21204, USA
    Cardiology 107:307-12. 2007
    ..We sought to compare the antiplatelet profile of aspirin 81 mg (n = 252) versus aspirin 325 mg (n = 459) before and during conventional clopidogrel loading (300 mg), and/or clopidogrel maintenance (75 mg/daily) therapy...
  15. ncbi Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Towson, MD 21204, USA
    Am Heart J 153:371-7. 2007
    ..The aim of this study was to describe the responses of ex vivo measures of platelet aggregation and activation to long-term clopidogrel therapy in a large population of outpatients after coronary stenting or ischemic stroke...
  16. ncbi Fluorimetric quantitation of citalopram and escitalopram in plasma: developing an express method to monitor compliance in clinical trials
    Victor Serebruany
    HeartDrug Research Laboratories, Towson, MD 21204, USA
    Clin Chem Lab Med 45:513-20. 2007
    ..We sought to develop a rapid method for the measurement of citalopram/escitalopram levels in human plasma by fluorimetry...
  17. ncbi AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis
    Victor L Serebruany
    HeartDrug Research Laboratories, Osler Medical Center, 7600 Osler Drive, Suite 307, Towson, MD 21204, USA
    Expert Rev Cardiovasc Ther 5:635-41. 2007
    ..AGI-1067 is currently being tested in the late trials, and if proven to improve clinical outcomes (ARISE trial), the drug will ultimately be used in patients with different manifestations of atherosclerosis and atherothrombosis...
  18. ncbi Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial
    Victor L Serebruany
    HeartDrug Research Laboratories, Towson, MD 21204, USA
    Am Heart J 155:93.e1-7. 2008
    ..The objective of this study was to compare the antiplatelet profiles of clopidogrel + aspirin in combination (C + ASA) versus aspirin alone (ASA) in patients with type 2 diabetes mellitus...
  19. ncbi Assessment of bleeding events in clinical trials--proposal of a new classification
    Victor L Serebruany
    Johns Hopkins University, Towson, Maryland, USA
    Am J Cardiol 99:288-90. 2007
    ....
  20. ncbi Hypokalemia, cardiac failure, and reporting NXY-059 safety for acute stroke
    Victor L Serebruany
    Johns Hopkins University, Department of Neurology, Osler Medical Center, 7600 Osler Drive, Suite 307, Towson, MD 21204, USA
    J Cardiovasc Pharmacol Ther 11:229-31. 2006
    ....
  21. ncbi Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD 21204, USA
    J Cardiovasc Pharmacol Ther 10:163-4. 2005
  22. ncbi Noncompliance in cardiovascular clinical trials
    Victor L Serebruany
    Heart Drug Research Laboratories, Towson, MD, USA
    Am Heart J 150:882-6. 2005
  23. ncbi Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives
    Michael V Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, 7600 Osler Drive, Suite 307, Towson, Maryland 21204, USA
    Expert Opin Pharmacother 7:81-9. 2006
    ..Further clinical studies are needed to present more clinical evidence necessary to broad the indication spectrum of this agent...
  24. ncbi Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
    Victor Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, 7600 Osler Drive, Suite 307, Towson, Maryland 21204, USA
    Thromb Res 119:175-81. 2007
    ..Ongoing search for the optimal dosing regimens, and valid concerns that some GPIIb/IIIa inhibitors may cause rebound platelet activation are limiting the use of these agents in patients with acute vascular events...
  25. ncbi Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study)
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Towson, MD, USA
    Am J Cardiol 97:1332-6. 2006
    ..These observational data offer a plausible mechanism for the recently demonstrated pleiotropic effects of statins that may contribute to early clinical benefit...
  26. ncbi Comment: mortality benefit of no-load clopidogrel in COMMIT: not a surprise
    Victor L Serebruany
    HeartDrug Research Laboratories, Towson, MD
    J Cardiovasc Pharmacol Ther 11:99-100. 2006
  27. ncbi Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease
    Victor L Serebruany
    HeartDrug Research Laboratories, Osler Medical Center, Johns Hopkins University, 7600 Osler Drive, Ste 307, Towson, Baltimore, MD 21204, USA
    J Thromb Thrombolysis 25:207-13. 2008
    ....
  28. doi Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-b
    Victor L Serebruany
    Heart Drug Research Laboratories, Towson, Maryland, USA
    Clin Ther 30:249-59. 2008
    ..Clopidogrel, aspirin (ASA), and the fixed-dose combination of extended-release dipyridamole and ASA (ER-DP+ASA) are widely used in post-stroke regimens...
  29. doi Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD, USA
    Fundam Clin Pharmacol 22:315-21. 2008
    ..This excess risk should be considered when choosing the optimal antiplatelet strategy for long-term treatment of patients with prior occlusive vascular events or those at high risk of developing occlusive vascular disease...
  30. doi Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy
    Victor Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD, USA
    J Thromb Thrombolysis 27:438-46. 2009
    ..We serially assessed release of established PEA biomarkers in subjects treated with AGI-1067 versus placebo in the frame of Assessment of Lipoprotein Profiles Randomized Trial (ALPS)...
  31. doi Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke
    Victor Serebruany
    Johns Hopkins University, Baltimore, MD, USA
    J Thromb Thrombolysis 33:22-7. 2012
    ..This preliminary evidence, while intriguing, requires confirmation in post-stroke patients receiving orally dosed D in order to determine whether these findings are clinically relevant...
  32. ncbi Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, MD 21204, USA
    Cardiovasc Revasc Med 12:94-8. 2011
    ....
  33. doi Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified
    V L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Towson, MD 21204, USA
    Thromb Haemost 105:752-9. 2011
    ..Future practice of self monitoring in pivotal indication-seeking clinical trials should be completely banned...
  34. doi Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy
    Victor Serebruany
    Johns Hopkins University, Baltimore, Maryland, 21204, USA
    Thromb Haemost 105:81-7. 2011
    ..In the small randomised study, both aspirin and Aggrenox produced fast and sustained recovery of plasma eNOS levels, while only therapy with Aggrenox was associated with oxLDL inhibition late in the trial...
  35. doi The TRITON versus PLATO trials: differences beyond platelet inhibition
    V L Serebruany
    HeartDrug TM Research Laboratories, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, Maryland, 21204, USA
    Thromb Haemost 103:259-61. 2010
    ....
  36. ncbi Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance"
    Victor Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Towson, MD 21204, USA
    Am Heart J 158:925-32. 2009
    ..However, noncompliance is difficult to prove without confirming that the drug has been administered. Therefore, detection of plasma clopidogrel and/or metabolite(s) as the reliable objective method to confirm compliance is important...
  37. ncbi Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications
    Victor Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University Towson, 7600 Osler Drive, Towson, MD 21204, USA
    Eur Heart J 31:227-35. 2010
    ..However, the potential association of bleeding risk and IPA is not established. It may play a critical role for the safety of more aggressive platelet inhibition or/and individual tailoring of antiplatelet strategies...
  38. ncbi The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease
    Victor L Serebruany
    HeartDrug Research Laboratories, John Hopkins University Baltimore, MD, USA
    Thromb Haemost 102:111-9. 2009
    ..Selective blockade of platelet receptors suggests unique antiplatelet properties of E5555 as a potential addition to current antithrombotic regimens...
  39. ncbi Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Osler Medical Building, Towson, 21204 MD, USA
    Fundam Clin Pharmacol 23:411-7. 2009
    ..More delicate platelet inhibition, and shorter exposure to oral antiplatelet agents will prevail...
  40. ncbi Antiplatelet 'resistance' and 'non-responders': what do these terms really mean?
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, MD 21204, USA
    Fundam Clin Pharmacol 23:11-8. 2009
    ..And, ultimately, we need to more firmly establish how the variability in platelet function and drug-associated changes in that function correlates with long-term, hard-endpoint clinical events...
  41. ncbi Prasugrel development - claims and achievements
    Victor Serebruany
    HeartDrug, Research Laboratories, Johns Hopkins University, Towson, Maryland, 21204, USA
    Thromb Haemost 101:14-22. 2009
    ..Very careful maintenance-dose selection with the main focus on long-term safety profile for the new agents will become a key to success for the future oral antiplatelet drug development...
  42. ncbi Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting
    Victor Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Osler Medical Building, Towson, MD 21204, USA
    Thromb Haemost 100:314-8. 2008
    ..These data closely match the frequency of dyspnea that was observed in the CAPRIE trial, suggesting that therapy with clopidogrel, and/or aspirin holds very small (if any) risk for dyspnea...
  43. doi Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease
    Victor Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, Maryland, 21204, USA
    Thromb Haemost 100:76-82. 2008
    ..Considering worsened outcomes in this high-risk population, clinical trials in DM are urgently needed in order to define the optimal degree of platelet inhibition and suitability for more aggressive antiplatelet regimens...
  44. doi Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger
    Victor L Serebruany
    Heart Drug, Research Laboratories, Johns Hopkins University, Towson, MD 21204, USA
    Cerebrovasc Dis 26:93-4. 2008
  45. doi Prasugrel for arterial coronary thrombosis
    Victor Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Maryland 21204, USA
    Drugs Today (Barc) 45:83-91. 2009
    ..Very careful maintenance dose selection and a flawless long-term safety profile for the new agents will become the keys to the success of future oral antiplatelet drug development...
  46. ncbi Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators
    V L Serebruany
    Union Memorial Hospital, Baltimore, MD, USA
    Stroke 29:235-8. 1998
    ..However, prospective data on the changes of platelet status in patients before the occurrence of hemorrhagic stroke after thrombolytic therapy are unavailable...
  47. ncbi Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy
    Victor L Serebruany
    Sinai Hospital, Johns Hopkins University, Baltimore, MD, USA
    Am Heart J 145:636-42. 2003
    ..Therefore, the success of fibrinolytic therapy may be dependent on its direct effects on platelets...
  48. ncbi Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy
    Victor L Serebruany
    Sinai Center for Thrombosis Research, Johns Hopkins University, Baltimore, MD 21215, USA
    Circulation 108:939-44. 2003
    ..Accordingly, we serially assessed the release of established platelet/endothelial biomarkers in patients treated with sertraline vs placebo in the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART)...
  49. ncbi Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy)
    Victor L Serebruany
    Sinai Center for Thrombosis Research, Johns Hopkins University, Baltimore, MD, USA
    Am Heart J 146:91-8. 2003
    ..We measured platelet characteristics during chronic treatment in patients with coronary artery disease enrolled in the Roxifiban Oral Compound Kinetics Evaluation Trial (ROCKET-I)...
  50. ncbi Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction
    P A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Scand Cardiovasc J 34:53-8. 2000
    ..634). The data suggest that the baseline characteristics predict future platelet activity, and may prospectively identify patients who will benefit most from antiplatelet strategies after coronary thrombolysis...
  51. ncbi Rapid platelet inhibition after a single capsule of Aggrenox: challenging a conventional full-dose aspirin antiplatelet advantage?
    Victor L Serebruany
    Sinai Hospital, Johns Hopkins University, Baltimore, Maryland 21215, USA
    Am J Hematol 72:280-1. 2003
    ..These findings could be relevant for the optimal balance between the reduction of vascular events via sufficient and rapid platelet inhibition and low risk of bleeding complications associated with the Aggrenox therapy...
  52. ncbi Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry
    Victor L Serebruany
    Johns Hopkins University, Sinai Hospital, Baltimore, MD, USA
    Pathophysiol Haemost Thromb 32:8-15. 2002
    ..Taken together, opposite to our expectations, major clinical characteristics of heart failure did not correlate well with the platelet characteristics investigated in this study...
  53. ncbi Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial)
    V Serebruany
    Sinai Hospital, Johns Hopkins University, Baltimore, MD 21215, USA
    Eur J Heart Fail 4:461-7. 2002
    ..We sought to characterize the diagnostic utility of the whole blood aggregometry (WBA) in a random outpatient CHF population...
  54. ncbi Serial changes of the plasma prostanoids during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor
    V L Serebruany
    Heart Associates Research and Education Foundation, Union Memorial Hospital, Baltimore, MD 21218, USA
    Prostaglandins Leukot Essent Fatty Acids 56:135-42. 1997
    ..Ability of Mg, diltiazem, and leumedins to favorably modulate plasma prostanoid levels have direct clinical implications for the use of these agents in patients with coronary artery disease...
  55. doi The in vitro effects of Xancor, a synthetic astaxanthine derivative, on hemostatic biomarkers in aspirin-naïve and aspirin-treated subjects with multiple risk factors for vascular disease
    Victor Serebruany
    Heart Drug Research Laboratories, Johns Hopkins University Baltimore, MD, USA
    Am J Ther 17:125-32. 2010
    ..These results are important for the assessment of the safety profile, but remain to be confirmed preclinically, in vivo, and ultimately in the clinic...
  56. ncbi Uniform platelet activation exists before coronary stent implantation despite aspirin therapy
    V L Serebruany
    Center for Thrombosis Research, Sinai Hospital, Baltimore, MD 21215, USA
    Am Heart J 142:611-6. 2001
    ..Enhanced platelet aggregation and receptor expression unquestionably occur after coronary stent implantation; however, the functional characteristics of platelets before stenting have not been fully elucidated...
  57. ncbi Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors
    V L Serebruany
    Sinai Center for Thrombosis Research, Johns Hopkins University, Baltimore, MD, USA
    Pharmacol Res 43:453-62. 2001
    ..The documented anti-platelet effects of sertraline and NDMS may be directly related to the mortality benefits of SSRIs after ischemic events including myocardial infarction and stroke...
  58. ncbi Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy
    V L Serebruany
    Center for Thrombosis Research, Sinai Hosital of Baltimore, MD 21215, USA
    Eur J Heart Fail 1:243-9. 1999
    ..However, no data are available on the plasma levels of Platelet/Endothelial Cell Adhesion Molecule-1 (PECAM-1), and platelet-derived osteonectin in this growing population...
  59. ncbi Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction
    V L Serebruany
    Sinai Center for Thrombosis Research, Schapiro Research Building, Baltimore, Maryland 21215, USA
    J Thromb Thrombolysis 9:229-34. 2000
    ..The ability of MAC to favorably modulate the pre-reperfusion platelet status in such patients is of clinical importance, and further investigation in large-scale clinical trials seem warranted...
  60. ncbi Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department
    P A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Am Heart J 139:320-8. 2000
    ..Elevated P-selectin level also has been observed in the clinical setting of myocardial ischemia and reperfusion; however, its utility in differentiating cardiac from noncardiac origins of chest pain is unknown...
  61. ncbi Changes in hemostasis after parenteral magnesium in myocardial ischemia-reperfusion: from animal studies to clinical trials
    V L Serebruany
    Center for Thrombosis Research, Sinai Hospital, Baltimore, MD, USA
    Magnes Res 11:133-40. 1998
    ..This review summarizes the latest, and often confusing data on the effects of Mg on certain hemostatic characteristics which may be directly relevant to the existing controversy...
  62. ncbi Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries
    P A Gurbel
    Union Memorial Hospital and St Agnes Hospital, Baltimore, Maryland, USA
    J Am Coll Cardiol 31:1466-73. 1998
    ..We sought to compare platelet characteristics after reteplase and alteplase therapy in the setting of the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)-III trial...
  63. ncbi Plasma fibronectin during myocardial ischemia-reperfusion: effects of magnesium, diltiazem, and a novel Mac-1 inhibitor
    V L Serebruany
    Union Memorial Hospital, Baltimore, Maryland, USA
    Am J Hematol 57:309-14. 1998
    ..Ability of Mg, diltiazem, and leumedins to modulate plasma Fn level may have direct clinical implications for the use of these agents in patients with coronary artery disease...
  64. ncbi Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials
    Victor L Serebruany
    Sinai Center for Thrombosis Research, Johns Hopkins University, Baltimore, Maryland 21215, USA
    Blood Coagul Fibrinolysis 14:563-7. 2003
    ..These findings may contribute to the unfavorable outcome associated with clinical depression in patients with ACS...
  65. ncbi Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits
    Victor L Serebruany
    Johns Hopkins University, Baltimore, Maryland, USA
    J Cardiovasc Pharmacol 43:677-84. 2004
    ..Whether valsartan reduces vascular ischemic events via additional pathways of platelet inhibition in patients with myocardial infarction and ischemic stroke requires further clinical research...
  66. ncbi Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial
    Victor L Serebruany
    HeartDrug Research Laboratories, 7600 Osler Drive, Ste 307, Towson, MD 21204, USA
    Eur J Pharmacol 499:315-24. 2004
    ..Aggrenox was associated with a profound reduction of PAR-1 receptors, an observation that may be related to the greater clinical benefit of Aggrenox compared with Aspirin in preventing recurrent stroke...
  67. ncbi Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study
    Victor L Serebruany
    HeartDrug Research, LLC, Baltimore, MD, USA
    Arch Intern Med 164:2051-7. 2004
    ..We sought to address this issue prospectively by performing serial measurements of 19 platelet characteristics using conventional aggregometry, rapid analyzers, and flow cytometry...
  68. ncbi Variability in platelet responsiveness to clopidogrel among 544 individuals
    Victor L Serebruany
    HeartDrug Research Laboratories, Osler Medical Building, 7600 Osler Drive, Towson, MD 21204, USA
    J Am Coll Cardiol 45:246-51. 2005
    ..We sought to describe the responses of patients to clopidogrel using ex vivo measures of platelet aggregation and activation in a large, heterogeneous population...
  69. ncbi Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials
    Victor L Serebruany
    HeartDrug Research Laboratories, Towson, Maryland, USA
    Am J Cardiol 95:1218-22. 2005
    ..These findings should be considered when using combination antiplatelets, anticoagulant therapy, or both, with ASA, especially with the daily dose of >100 mg...
  70. ncbi Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy
    Victor L Serebruany
    Internal Medicine, Johns Hopkins University, 7600 Osler Drive, Ste 307, Baltimore, MD 21204, USA
    Thromb Res 113:197-204. 2004
    ..Although aspirin reduces risks of myocardial infarction, stroke and cardiovascular death, the extent of platelet action and the effect of aspirin on platelet function in patients recovering from stroke remain unclear...
  71. ncbi Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, 7600 Osler Dr, Suite 307, Towson, MD 21204, USA
    Am J Psychiatry 162:1165-70. 2005
    ....
  72. ncbi Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial
    Victor L Serebruany
    HeartDrug Research Laboratories, Towson, MD 21204, USA
    Stroke 36:2289-92. 2005
    ..To determine whether clopidogrel with aspirin (C+ASA) will produce more potent platelet inhibition than aspirin alone (ASA) in patients after ischemic stroke, we conducted the Plavix Use for Treatment of Stroke trial...
  73. ncbi Statins increase risk of hemorrhagic stroke by inhibition of the PAR-1 receptor
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD, USA
    Cerebrovasc Dis 24:477-9. 2007
  74. ncbi Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease
    Alex I Malinin
    Center for Thrombosis Research, Sinai Hospital of Baltimore, Johns Hopkins University, 2401 West Belvedere Avenue, Schapiro Research Building R 202, Baltimore, MD 21215, USA
    Eur J Pharmacol 462:139-43. 2003
    ..The Ultegra Analyzer with a novel cartridge seems to be reliable in reflecting aspirins' effects on platelets and could be used in the future in clinical practice for monitoring aspirin therapy...
  75. ncbi Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215 5271, USA
    Am Heart J 145:239-47. 2003
    ..We sought to establish an optimal clopidogrel dosing regimen for sustained platelet inhibition in stented patients...
  76. ncbi Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets
    Marcus E McKenzie
    Center for Thrombosis Reseasrch, Sinai Hospital of Baltimore, Johns Hopkins University, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    Blood Coagul Fibrinolysis 14:249-53. 2003
    ..In addition to the known effect of irreversibly inhibiting platelet cyclooxygenase-1, thereby blocking thromboxane A(2) synthesis, it appears that aspirin exhibits direct effects on selective major platelet receptors...
  77. ncbi Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy)
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Thromb Thrombolysis 14:213-9. 2002
    ..The effect of eptifibatide on these receptors was investigated in a substudy of the EARLY Trial...
  78. ncbi Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Am J Cardiol 90:312-5. 2002
  79. ncbi Effects of in vitro exposure of alcohol on surface receptor expression of human platelets
    Marcus E McKenzie
    Sinai Hospital, Johns Hopkins University, Baltimore, MD, USA
    Clin Physiol Funct Imaging 22:153-6. 2002
    ..This study for the first time establishes a direct effect of ethanol on selective major platelet receptors. Beneficial cardiovascular properties of moderate alcohol consumption may be explained by ethanol's antiplatelet action...
  80. ncbi Stability validation of paraformaldehyde-fixed samples for the assessment of the platelet PECAM-1, P-selectin, and PAR-1 thrombin receptor by flow cytometry
    Oliver D Atar
    Johns Hopkins University, Baltimore, MD, USA
    J Thromb Thrombolysis 30:79-83. 2010
    ..This is critical logistic information for conducting multicenter platelet substudies within the framework of major clinical trials...
  81. ncbi Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study
    Paul A Gurbel
    Sinai Hospital, Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 W Belvedere Avenue, Baltimore, MD, 21215, USA
    J Invasive Cardiol 14:584-9. 2002
    ..This finding may be related to superior scaffolding, resulting in a smoother luminal contour after implantation of a closed-cell stent...
  82. ncbi Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity?
    Alex I Malinin
    Heart Drug Research Laboratories, Johns Hopkins University, Baltimore, Maryland 21215, USA
    Blood Coagul Fibrinolysis 18:91-6. 2007
    ..This uniform platelet inhibition with clopidogrel may be an important consideration in designing future large-scale clinical trials...
  83. doi Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge
    V Serebruany
    Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, Maryland, 21204, USA
    Thromb Haemost 103:415-8. 2010
    ....
  84. ncbi Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction
    Raymond D Bahr
    St Agnes Hospital, Baltimore, Maryland, USA
    Am J Cardiol 90:310-2. 2002
  85. ncbi The PLATO trial: do you believe in magic?
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Towson, MD 21204, USA
    Eur Heart J 31:764-7. 2010
    ....
  86. ncbi Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD, USA
    Am Heart J 151:92-9. 2006
    ..To test whether valsartan inhibits platelet activity in mild to moderate hypertensives we conducted the randomized Valsartan Inhibits Platelets (VIP) trial...
  87. ncbi Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University Baltimore, MD, USA
    Am J Ther 17:543-52. 2010
    ..Western blot analysis findings suggest the presence of 5-HT₄ receptor protein on human platelets. Further investigations on the potential role of 5-HT₄ receptors in human platelets may be warranted...
  88. doi Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers. The AGgrenox versus Aspirin Therapy Evaluation (AGATE-Japan)
    Victor L Serebruany
    HeartDrug Research Laboratories, Baltimore, Maryland, USA
    Thromb Haemost 99:116-20. 2008
    ..A larger study to assess drug efficacy and safety in the Japanese post-stroke patients is warranted...
  89. ncbi Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes?
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Am Heart J 143:1068-75. 2002
    ..We sought to determine whether platelet activity in patients with heart failure is related to an ischemic versus nonischemic etiologic condition, clinical disease severity, or adverse clinical outcomes...
  90. ncbi Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial
    Victor L Serebruany
    Sinai Center for Thrombosis Research, Johns Hopkins University, Sinai Hospital, Baltimore, MD 21215, USA
    Am Heart J 146:713-20. 2003
    ..We assessed antiplatelet properties of clopidogrel with aspirin (C+A) versus aspirin alone (A) in patients with CHF with heightened platelet activity...
  91. ncbi Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials
    Victor L Serebruany
    Sinai Center for Thrombosis Research, Johns Hopkins University, Baltimore, Maryland 21215, USA
    Am J Hematol 75:40-7. 2004
    ..These findings should be considered when using combination antiplatelet and/or anticoagulant therapy with conventional doses of ASA...
  92. ncbi Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations
    Victor L Serebruany
    Johns Hopkins University, Towson, MD 21204, USA
    Am J Ther 17:68-74. 2010
    ....
  93. ncbi Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events?
    Victor L Serebruany
    HeartDrug Research, Johns Hopkins University, Baltimore, Maryland, USA
    Am J Med 119:707.e11-6. 2006
    ....
  94. ncbi Late prasugrel benefit in STEMI patients?
    Victor L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, Towson, MD 21204, USA
    Am J Ther 16:469-70. 2009
    ....
  95. ncbi Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel
    A Malinin
    Heart Drug Research Laboratories, Baltimore, Maryland, USA
    Methods Find Exp Clin Pharmacol 28:315-22. 2006
    ..VerifyNow-P2Y12 is a reliable, simple, and sensitive device suitable for monitoring of P2Y12 platelet receptor inhibitors in the clinical arena...
  96. ncbi Criticality of pH for accurate fluorometric measurements of dipyridamole levels in biological fluids
    B Oshrine
    HeartDrug Research Laboratories, 7600 Osler Drive, Towson, MD 21204, USA
    Methods Find Exp Clin Pharmacol 27:95-100. 2005
    ....
  97. ncbi Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin
    V L Serebruany
    Sinai Center for Thrombosis Research, Johns Hopkins University, 2401 West Belvedere Avenue, Schapiro Research Building R 202, Baltimore, MD 21215, USA
    Eur J Heart Fail 5:517-21. 2003
    ..This observation may help to explain some of the clinical benefits associated with SSRI therapy. Further clinical trials may help to elucidate the potential outcome benefits of SSRIs in other potential thrombotic circumstances...
  98. pmc Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study
    V L Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University, USA
    Postgrad Med J 82:404-10. 2006
    ..This study compared the antiplatelet properties of prasugrel in a small subset of patients enrolled in the JUMBO trial, and compared with historic clopidogrel treated controls...
  99. ncbi Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction
    V L Serebruany
    Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD, USA
    Arterioscler Thromb Vasc Biol 19:153-8. 1999
    ..Further investigation of the possible role of PECAM-1 and the relationship between its soluble and platelet fractions in AMI are warranted...
  100. ncbi The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease
    Victor Serebruany
    HeartDrug Research Laboratories, Johns Hopkins University Baltimore, Maryland, USA
    J Cardiovasc Pharmacol Ther 11:191-6. 2006
    ..The effect of AGI-1067 differs from other known antiplatelet agents, suggesting opportunities for therapeutic combination. These data need to be confirmed in subjects receiving orally dosed AGI-1067 to be clinically relevant...
  101. ncbi Antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: a randomized, placebo-controlled, double-blind trial
    Nicole Kotzailias
    Department of Clinical Pharmacology, Medical University Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    J Clin Pharmacol 46:468-75. 2006
    ..05 between periods). The combination of paroxetine and aspirin did not further inhibit platelet plug formation under high shear stress in male smokers...